| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$71 |
Cleansing Notice
|
9 Jul 2024 10:05AM |
$0.460 |
$0.285 |
fallen by
38.04%
|
|
| Elanor Commercial Property Fund (ECF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$230 |
Change in substantial holding
|
9 Jul 2024 10:01AM |
$0.670 |
$0.565 |
fallen by
15.67%
|
|
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$71 |
Application for quotation of securities - RCE
|
9 Jul 2024 9:59AM |
$0.460 |
$0.285 |
fallen by
38.04%
|
|
| Metallica Minerals Limited (MLM) ORDINARY FULLY PAID |
Materials |
- |
Change in substantial holding
|
9 Jul 2024 9:58AM |
$0.020 |
$0.034 |
risen by
70%
|
|
| EV Resources Limited (EVR) ORDINARY FULLY PAID |
Materials |
$8 |
Further High Grade Copper, Molybdenum, Silver Drill Results
|
9 Jul 2024 9:58AM |
$0.006 |
$0.004 |
fallen by
27.27%
|
|
EVR - Price-sensitive ASX Announcement
Full Release
Key Points
- High grade copper-molybdenum-silver mineralization found in breccia and surrounding rocks.
- Drill holes APG-DDH-004, APG-DDH-005, and APG-DDH-007 show significant mineralization.
- Highlights include 180m at 0.31% Cu, 0.09% Mo, and 4.20g/t Ag from APG-DDH-007.
- Copper and molybdenum prices are significantly high, adding economic value.
- EVR is reviewing silver content of previous drill holes as silver prices rise.
- Trinchera Este mineralization outside the breccia indicates potential for larger scale systems.
- Further work includes more drilling to explore beyond the known breccia system.
- Geophysical studies are planned to better understand the extent of the mineralization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dateline Resources Limited (DTR) ORDINARY FULLY PAID |
Materials |
$25 |
Prospectus to Renounceable Rights Issue
|
9 Jul 2024 9:56AM |
$0.007 |
$0.009 |
risen by
28.57%
|
|
DTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Renounceable pro-rata entitlement offer at $0.006 per New Share
- Offer to raise approximately $5.83 million (before costs)
- 33% discount to the closing price on ASX prior to announcement on 8 July 2024
- Shareholders receive 2 New Shares for every 3 Existing Shares held, with 1 New Option for every 2 New Shares
- Rights trading commences on 11 July 2024
- Minimum subscription of $1,974,691
- Funds to be used for Colosseum Gold and Rare Earths Project development, mine study, reducing debt, and general working capital
- Potential maximum voting power increase to 27.17% for Chairman Mark Johnson AO
- Mahe Capital appointed as lead manager to place any Shortfall
- Risks include funding requirements, exploration risk, and general market risks
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,326 |
Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
9 Jul 2024 9:55AM |
$1.095 |
$1.820 |
risen by
66.21%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Mesoblast Limited resubmitted its Biologic License Application (BLA) to the FDA for Ryoncil (remestemcel-L) targeting pediatric patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
- The resubmission followed FDA communication indicating sufficient clinical trial data for submission
- The BLA addresses remaining Chemistry, Manufacturing, and Control (CMC) items
- Ryoncil has been granted Fast Track and Priority Review designations by the FDA
- The FDA review period for the BLA is expected to be between two to six months
- Ryoncil is developed from culture-expanded mesenchymal stromal cells derived from the bone marrow of unrelated donors
- The Phase 3 trial for Ryoncil showed a 70.4% overall response rate by Day 28 in children with SR-aGVHD
- The survival of children treated with Ryoncil at Day 100 was significantly better than those who received the best available treatment
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Stellar Resources Limited (SRZ) ORDINARY FULLY PAID |
Materials |
$33 |
Notice of Extraordinary General Meeting/Proxy Form
|
9 Jul 2024 9:55AM |
$0.021 |
$0.016 |
fallen by
23.81%
|
|
| Dateline Resources Limited (DTR) ORDINARY FULLY PAID |
Materials |
$25 |
Proposed issue of securities - DTR
|
9 Jul 2024 9:53AM |
$0.007 |
$0.009 |
risen by
28.57%
|
|
| Endeavour Group Limited (EDV) ORDINARY FULLY PAID |
Consumer Staple |
$7,236 |
Notification of cessation of securities - EDV
|
9 Jul 2024 9:52AM |
$5.015 |
$4.040 |
fallen by
19.44%
|
|
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$31 |
Notification of cessation of securities - BTN
|
9 Jul 2024 9:50AM |
$0.046 |
$0.110 |
risen by
139.13%
|
|
| RAM Essential Services Property Fund (REP) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$293 |
Change of Director's Interest Notice
|
9 Jul 2024 9:46AM |
$0.620 |
$0.585 |
fallen by
5.65%
|
|
| Global Lithium Resources Limited (GL1) ORDINARY FULLY PAID |
Materials |
$44 |
Trading Halt
|
9 Jul 2024 9:40AM |
$0.265 |
$0.170 |
fallen by
35.85%
|
|
GL1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Global Lithium Resources Limited (GL1)
- Pending an announcement regarding Board changes
- Halt expected to lift by or before 11 July 2024
- Request made under ASX Listing Rule 17.1
- No other reasons or relevant information affecting the trading halt
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Moab Minerals Limited (MOM) ORDINARY FULLY PAID |
Materials |
$2 |
Notification regarding unquoted securities - MOM
|
9 Jul 2024 9:39AM |
$0.005 |
$0.001 |
fallen by
80%
|
|
| Moab Minerals Limited (MOM) ORDINARY FULLY PAID |
Materials |
$2 |
Notification regarding unquoted securities - MOM
|
9 Jul 2024 9:39AM |
$0.005 |
$0.001 |
fallen by
80%
|
|
| Moab Minerals Limited (MOM) ORDINARY FULLY PAID |
Materials |
$2 |
Application for quotation of securities - MOM
|
9 Jul 2024 9:39AM |
$0.005 |
$0.001 |
fallen by
80%
|
|
| Moab Minerals Limited (MOM) ORDINARY FULLY PAID |
Materials |
$2 |
Completion of Acquisition of Advanced Uranium Assets
|
9 Jul 2024 9:39AM |
$0.005 |
$0.001 |
fallen by
80%
|
|
MOM - Price-sensitive ASX Announcement
Full Release
Key Points
- Moab Minerals Limited (ASX: MOM) completed the acquisition of 81.85% of Linx Resources Pty Ltd.
- Moab increased its ownership to 89.6% by converting a $521,000 loan to equity.
- The acquired assets include the Manyoni and Octavo Uranium Projects in Tanzania covering 216 km2.
- The Manyoni Uranium Project has access to modern infrastructure and was extensively drilled by Uranex Ltd until 2013.
- Drilling is set to commence at the Manyoni project in August/September.
- Moab has about $1.9 million in funds to support exploration and development efforts.
- Completion of acquisition terms involved various financial transactions and conversion of loans.
- Legal issues are present with two of the three mineral prospecting licences being contested by AuKing Mining Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$35 |
NTA at 28.06.2024 Pre-tax 1.0716 Post-tax 1.0792
|
9 Jul 2024 9:38AM |
$0.995 |
$1.000 |
risen by
0.50%
|
|
| Platina Resources Limited (PGM) ORDINARY FULLY PAID |
Materials |
$13 |
PGM accelerates exploration at its WA gold projects
|
9 Jul 2024 9:38AM |
$0.029 |
$0.021 |
fallen by
27.59%
|
|
| Suvo Strategic Minerals Limited (SUV) ORDINARY FULLY PAID |
Materials |
- |
Binding Joint Development Agreement Signed with PERMAcast
|
9 Jul 2024 9:37AM |
$0.045 |
$0.031 |
fallen by
31.11%
|
|
SUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Tripartite binding Joint Development Agreement (JDA) executed between Suvo, its wholly owned subsidiary Climate Tech Cement Pty Ltd (CTC), and Polevine Pty Ltd (PERMAcast).
- CTC and PERMAcast propose to deliver low carbon geopolymer concrete (GPC) products and projects to market.
- JDA requires PERMAcast to provide the capital required to fund the project, including testing various GPC formulations to meet concrete strength requirements.
- The first GPC product to be delivered using the Colliecrete formulation will be geopolymer concrete backing blocks for a government infrastructure project.
- PERMAcast will fund the project, and any intellectual property created will be owned by the JV Entity.
- The JV Entity will focus on preparing, testing, characterizing, and assessing various GPC formulations and their applications.
- CTC and PERMAcast aim to incorporate the JV Entity and complete a shareholder’s agreement within the next 30 days.
- Suvo's licensed low carbon concrete formulation, Colliecrete, has potential for up to ~70% greenhouse gas emission reduction compared to traditional concrete.
- The JDA marks an important milestone in Suvo's commercialisation journey of its low carbon geopolymer concrete technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Australia Bank Limited (NAB) ORDINARY FULLY PAID |
Financials |
$109,975 |
Notification of cessation of securities - NAB
|
9 Jul 2024 9:37AM |
$35.600 |
$35.910 |
risen by
0.87%
|
|
| identitii Limited (ID8) ORDINARY FULLY PAID |
Information Technology |
$6 |
Rights Issue Closure and Shortfall Notification
|
9 Jul 2024 9:36AM |
$0.009 |
$0.008 |
fallen by
11.11%
|
|
ID8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Identitii Limited closed its recent Rights Issue on 4 July 2024, raising $1,659,445 before costs.
- The Rights Issue had a shortfall balance of $491,745.
- The Rights Issue was a pro-rata non-renounceable entitlement issue to eligible shareholders at an issue price of $0.01 per New Share.
- John Rayment, CEO of Identitii, took up 56% of his entitlement.
- The Company will issue and allot 165,944,526 New Shares on 11 July 2024.
- The Shortfall Offer will remain open for up to three months following the Closing Date.
- Funds raised will be used for working capital, closing deals in contract negotiation, and pursuing technology partnership opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Technologies Limited (GTG) ORDINARY FULLY PAID |
Health Care |
$6 |
GeneType to Enter Canadian and New Zealand Markets
|
9 Jul 2024 9:34AM |
$0.071 |
$0.039 |
fallen by
45.07%
|
|
GTG - Price-sensitive ASX Announcement
Full Release
Key Points
- GeneType to enter Canadian and New Zealand markets
- Genetic risk assessment tests distributed by Stayhealthy Canada and Stayhealthy New Zealand
- Recent success in digital transformation and influencer campaign with 500% sales increase
- First geneType assessment for breast cancer developed in 2022
- Comprehensive suite of tests for nine specific diseases
- Tests are non-invasive, saliva-based, clinically validated, and regulatory approved
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Australia Bank Limited (NAB) ORDINARY FULLY PAID |
Financials |
$109,975 |
Application for quotation of securities - NAB
|
9 Jul 2024 9:34AM |
$35.600 |
$35.910 |
risen by
0.87%
|
|
| Lowell Resources Fund (LRT) ORDINARY UNITS FULLY PAID |
Financials |
$52 |
LRT NAV Estimate - 5 July 2024
|
9 Jul 2024 9:32AM |
$1.210 |
$1.260 |
risen by
4.13%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
